Climb Bio, Inc.

US$10.29As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:CLYMHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (16.17%)
Div yield —
ROE (29.28%)
Biotechnology
Beta (5Y) (0.01)
PE TTM —
TSR TTM 401.95%
Mkt cap US$604.4M
ROIC (20.52%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$11
9.06%
(61.94%)
Hold 8|11|1|3|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.12
0.13
0.14
0.15
7.92%
11.72%
7.20%
13.79%
Revenue$M
37.42
37.98
38.27
39.43
10.33%
14.85%
10.29%
9.16%
Peers (US$604.4M)
Cap (US$)
PE
628.6M
1.778x
603.7M
29.76x
Capital
TTM
5Y
10Y
Leveragex
0.311
6.536
5.468
EBIT/Intx
0.324
0.297
0.322
Own earn%
(58.58)
68.90
47.01
Sh yield%
57.62
38.09
37.84
Owners
Insiders/Inst%
2.77
34.34
Short interest%
4.10
SBC / revenue%
5.36
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
24
Op margin range%
8–16
$1 testx
—
Incr. ROIC%
2